SLU-PP-332 is a laboratory research compound that turns on a set of cellular “switches” (ERRα/β/γ) which control how cells make and use energy. In animal studies, activating these switches makes muscle cells act like they’ve been exercised — they build more mitochondria (the cell’s power plants), burn more fat, and show improved endurance markers. Researchers study SLU-PP-332 to better understand energy metabolism and to explore new approaches to metabolic disease in controlled research settings.
Mechanism of action
- Target: Estrogen-related receptors (ERRα, ERRβ, ERRγ), nuclear receptors that regulate genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation.
- Activity: SLU-PP-332 acts as an agonist at ERR family receptors, upregulating transcriptional programs that favor oxidative metabolism and mitochondrial function.
- Downstream effects (preclinical): increased expression of mitochondrial genes, enhanced oxidative capacity in skeletal muscle, higher basal energy expenditure, and improved metabolic markers in diet-induced obesity models.
Representative preclinical studies & references
The items below are representative peer-reviewed studies describing SLU-PP-332 or related ERR-agonist research. These are primarily preclinical/animal studies.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Billon C., et al. J Pharmacol Exp Ther. 2024. Shows dose-dependent improvements in energy expenditure, fatty acid oxidation, fat mass reduction and insulin sensitivity in obese mouse models. PubMed: 37739806.
- Synthetic ERR-α/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response. Billon C., et al. ACS Chem Biol / PMC article. Reports that SLU-PP-332 activates exercise-responsive gene programs and enhances endurance metrics in sedentary mice, consistent with an “exercise-mimetic” profile. PMC (free full text): https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/.
- ERR Agonism Reverses Mitochondrial Dysfunction in Aging Kidney (Example of tissue benefit). Wang XX., et al. Am J Pathol. 2023. Demonstrates improvement in mitochondrial function and reduced inflammation in aging kidney models after ERR activation. PubMed: 37717940.
(Search PubMed for “SLU-PP-332” or “ERR agonist” to find additional mechanistic and tissue-specific reports.)
Potential research applications (examples)
- Metabolism & obesity models — examine effects on energy expenditure, body composition, insulin sensitivity.
- Mitochondrial biology — study mitochondrial biogenesis, respiratory capacity, and gene regulation (PGC-1α related pathways).
- Exercise physiology research — explore exercise-mimetic pathways and gene expression in muscle.
- Aging research — assess tissue-specific mitochondrial rescue in age-related decline models.
Note: These uses are for controlled laboratory and animal research. Translational or clinical applications require formal regulatory approval and clinical trials.
Safety, handling & regulatory guidance
- Not for human use — SLU-PP-332 has not been approved by the FDA for therapeutic use. Any human administration outside an approved IND or clinical trial is non-compliant.
- Laboratory practices — follow material safety data sheet (MSDS) guidance, institutional biosafety, and animal care (IACUC) protocols. Maintain certificates of analysis (CoA) and chain of custody for research reagents.
- Toxicology — comprehensive long-term toxicology and safety pharmacology in multiple species are required before any human studies; consult primary literature and supplier data for available safety endpoints.
Suggested metadata (meta title & description) — SEO ready
- Meta title: SLU-PP-332 (20 mg) — Research Compound Overview | ERR Agonist & Exercise-Mimetic
- Meta description: Research overview of SLU-PP-332 (20 mg), a synthetic ERR agonist studied as an exercise-mimetic. Mechanism, preclinical evidence, PubMed citations, and research-use compliance. Not FDA-approved.
SEO-optimized FAQ
Q1 — What is SLU-PP-332 (SLUPP332) 20 mg?
A1 — SLU-PP-332 is a synthetic small-molecule ERR agonist supplied for laboratory research; the “20 mg” refers to the total compound amount supplied in a research vial or labeled product. It is intended for research use only and is not an FDA-approved drug.
Q2 — How does SLU-PP-332 work?
A2 — It activates estrogen-related receptors (ERRα/β/γ), which upregulate genes involved in mitochondrial biogenesis and oxidative metabolism, producing exercise-like transcriptional and metabolic effects in preclinical models.
Q3 — What evidence supports SLU-PP-332’s effects?
A3 — Preclinical studies in rodents report dose-dependent increases in energy expenditure, fatty acid oxidation, reduced fat accumulation, and improved insulin sensitivity; see Billon et al. (J Pharmacol Exp Ther 2024) and related reports. PubMed: 37739806.
Q4 — Is SLU-PP-332 FDA-approved?
A4 — No. SLU-PP-332 is an investigational research compound and is not approved for human therapeutic use by the U.S. Food and Drug Administration. Any human studies would require formal regulatory approval.
Q5 — Where can I learn more / find primary studies?
A5 — Search PubMed for keywords: “SLU-PP-332”, “SLU PP 332”, or “ERR agonist”. Representative links include: J Pharmacol Exp Ther (Billon et al., PubMed: 37739806) and PMC article on ERR-dependent exercise responses (PMC10801787).
References (select)
- Billon C., et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024. PubMed: https://pubmed.ncbi.nlm.nih.gov/37739806/.
- Billon C., et al. Synthetic ERR-α/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response. PMC Free Full Text: https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/.
- Wang XX., et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction. Am J Pathol. 2023. PubMed: https://pubmed.ncbi.nlm.nih.gov/37717940/.
Compliance reminder (must read)
This summary is provided for research and educational purposes only. It does not provide clinical recommendations, dosing for human use, or procurement instructions for therapeutic use. Any transition from preclinical research to human studies requires formal regulatory review (IND/IRB), ethical approval, and adherence to FDA and local regulations.